Clinical trial
A Multicenter, Active-controlled, Open-label Phase I Study to Assess Safety and Tolerability and to Explore Immunogenicity of CVI-VZV-001 Vaccine in Healthy Adults Aged 50 to 64 Years
NCT06137755 is registered in ClinicalTrials.gov with Aribio Lab Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Active-controlled, Open-label Phase I Study to Assess Safety and Tolerability and to Explore Immunogenicity of CVI-VZV-001 Vaccine in Healthy Adults Aged 50 to 64 Years
- Lead sponsor
- Aribio Lab Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- March 15, 2023
- Completion date
- March 21, 2025
- Enrollment
- 32 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.